According to a report by the National Medicines Administration, irbesartan is a medicine that the Institute of Social Security of El Salvador decided to remove from its pharmacies because it is contaminated. This product is delivered to patients with arterial problems.
According to the ISSS authorities, appropriate measures have already been taken to remove it from pharmacies to the social security network.
However, the insurance authorities made an important warning to patients who receive the drug from this drug: the drug will not be replaced quickly, and each patient will have to undergo a medical examination to determine which replacement drug is most indicated in each case. They emphasized that patients should not stop using them.
In addition, the number 2244-4780 was included, so that patients can reschedule the prescription and replace the medication.
They recommend not to stop the use of irbesartan in a radical way and to reprogram its assessment as soon as possible so that it can be replaced.
The report provided by DNM refers to 53 drugs contaminated with impurities such as nitrosamines, nitrosodimethylamine and nitrosodiethylamine.
The group of contaminated drugs includes valsartan, losartan, irbesartan, olmesartan and candesartan. According to DNM, these drugs are manufactured by ZHEJIANG HUAHAI PHARMACEUTICAL CO. LTD, ZHEJIANG TIANYU PHARMACEUTICAL CO.LTD and HETERO LABS LIMITED, citizenship of China and India, respectively.
According to a report released by DNM, its use cannot be abruptly suspended, as this may affect patients who use it. It is recommended to contact the doctor who prescribed them so that he can replace them with other people of the same or better quality who meet the relevant safety requirements.